



June 23, 2015

AnGes MG, Inc.

AnGes Enters into Agreement with Mitsubishi Tanabe Pharma for the Exclusive Marketing Rights to HGF Plasmid for PAD in Japan

AnGes MG Inc. ("AnGes") announced today that the company has entered into a definitive agreement with Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka, President & CEO, Masayuki Mitsuka, "MTPC") for the exclusive marketing rights to HGF genetic medicine (DNA Plasmid with HGF gene) as a treatment for Peripheral Arterial Disease (PAD) in Japan.

As announced on February 17, 2015, AnGes and MTPC signed a basic agreement for the exclusive rights to the sales of AnGes's HGF genetic medicine in Japan. The two companies reached an agreement on the details of the terms, and concluded the contract upon the resolution of AnGes's Board of Directors on June 22, 2015.

Under the agreement, AnGes is to receive a one-off payment and performance-based milestone payments. AnGes will also receive sales-based payments if the product reaches the market. The one-off payment is recorded in the second quarter of 2015. Details of the payment and other financial terms of the contract are not disclosed.

AnGes and MTPC entered into the agreement for the exclusive marketing of HGF Plasmid in the United States in October 2012. MTPC now holds the marketing rights for Japan and the United States.

AnGes will post the one-off payment as revenue for the fiscal year ending December 2015. The impact of this event has already been included in the forecast for 2015.

###

Disclaimer: This is a translation of the news release posted in Japanese. In case of any deviations between the two language versions, the original document in Japanese shall take precedence.

<p>AnGesMG, Inc. Corporate Communications TEL:+81-3-5730-2641, FAX:+81-3-5730-2635 http://www.anges-mg.com</p>
--